I don't understand why a non-U.S. company can't be trusted, apparently neither do two of the top cancer centers in the U.S. Sloan in New York and M.D. Anderson in Texas who are evaluating their product.
As a investor in RDGL I don't believe they had it together at all. We can only hope that Vivos does.
AlphaDart didn't purse animal sales, probably because it wouldn't be cost effective. The complication of using a dart that remains in place and requires special applicator is limiting and could make it far more expensive. The dart itself probably adds significant cost.
I don't think anyone should be thinking that FDA approval for radiogel even when limited to advanced basal and squamous cell skin cancers is going to happen without clinical trials. We can hope for it, but don't invest like its definite.
I think we can have hope animal applications can fund those trials. As radiogel could open up cancer treatment to more animals because of its ease of use and relative affordability.
News 
Market Data 
Discover 
AI
